.jpg?format=webp&width=780)
The study aimed to investigate the effects of astaxanthin treatment on lipids, CVD markers, glucose tolerance, insulin action, and inflammation in individuals with prediabetes and dyslipidemia. The study was conducted on 34 adult participants with dyslipidemia and prediabetes. The participants were randomized into two groups, one group receiving astaxanthin treatment and the other group receiving a placebo. After 24 weeks, the study found that astaxanthin treatment significantly decreased LDL and total cholesterol levels and also reduced levels of the CVD risk markers fibrinogen, L-selectin, and fetuin-A. Although the effects of astaxanthin treatment did not reach statistical significance, there were trends towards improvements in insulin-stimulated whole-body glucose disposal, fasting insulin, and HOMA2-IR, suggesting improved insulin action. The study concluded that astaxanthin is a safe over-the-counter supplement that improves lipid profiles and markers of CVD risk in individuals with prediabetes and dyslipidemia.
Like
Save
Share